In advanced metastatic PC, PSMA-directed agents have demonstrated encouraging clinical activity, which culminated in the recent approval of PSMA-directed radioligand therapy 177-Lu-PSMA-617 39,40. The gene discussed is FOLH1; the disease is pachyonychia congenita.